Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease

Atherosclerosis

Volumn 122, Issue 1, 1996, Pages 105-115

  Koren, Eugen ^a,b   Corder, Clinton ^a,c   Mueller, Gudrun ^a   Centurion, Hose ^d   Hallum, Glen ^d   Fesmire, James ^a   McConathy, Walter D ^a   Alaupovic, Petar ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b GENENTECH INC   (United States)

^c Oklahoma Foundation for Cardiovascular Research   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Apolipoproteins; Coronary artery disease; Lipids; Lipoprotein particles; Lipoproteins

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029940679     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05791-9     Document Type: Article

References (52)

1. Kannel WB, Castelli WP, Gordon, T, McANamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971;74:1.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. J Am Med Assoc 1987;257:2176.
3. Lipid Research Program The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351.
4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977;62:707.
5. Miller NE, Forde OH, Thelle DS, Mjos OD. The Tromso Heart Study: high-density lipoproteins and coronary heart disease: a prospective case control study. Lancet 1977;1:965.
6. Miller NE, Hammet F, Saltissi S, Rao S, Vanzeller H, Coltart J, Lewis B. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J 1981;282:1741.
7. Carlson LA, Boltiger LE, and Ahfeld PE. Risk factors for myocardial infarction in the Stockholm Prospective Study: a 14-year follow-up focusing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979;206:351.
8. Halley SB, Resnmann RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 1980;302:1383.
9. Suenram A, McConathy WJ, Alaupovic P. Evidence for the lipoprotein heterogeneity of human plasma high density lipoproteins isolated by three different procedures. Lipids 1979;14:505.
10. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA-and ApoB-containing lipoprotein families. Prog Lipid Res 1991;30:105.
11. Koren E, Puchois P, Alaupovic P, Fesmire J, Kandoussi A, Fruchart JC. Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. Clin Chem 1987;33:38.
12. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II particles with A-I but no A-II. J Lipid Res 1982;23:747.
13. Fielding CJ, Fielding PE. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci USA 1981;78:3911.
14. Norfeldt P.I.P Olofsson SO, Fager G, Bondjers G. Isolation and partial characterization of the lipoprotein families A and A-I from high-density lipoproteins of human serum. Eur J Biochem 1981;118:1.
15. Nestruck AC, Niedmann PD, Wieland H, Seidel D. Chromatofocusing of human high density lipoproteins and isolation of lipoproteins A and A-I, Biochim Biophys Acta 1983;753:65.
16. Marcel YL, Weech PK, N'guyen T-D, Milne RW, McConathy WJ. Apolipoproteins as the basis for heterogeneity of high density lipo-protein2 and high density lipoprotein3. Studies by isoelectric focusing on agarose films. Eur J Biochem 1984;143:467.
17. Cheung MD, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res 1982;23:747.
18. Atmeh RF, Shepherd J, Packard CJ. Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic profiles and response to drug therapy. Biochim Biophys Acta 1983;751:175.
19. II particles. Biochem Biophys Res Commun 1987;142:63.
20. Puchois P. Kandoussi A, Fievet P, Fourier JL, Bertrand M, Koren E, Fruchart JC. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987;68:35.
21. Koren E, Alaupovic P, Lee DM, Dashti N, Kloer HU, Wen G. Selective isolation of human plasma low-density lipoprotein particles containing apolipoproteins B and E by use of a monoclonal antibody to apolipoprotein B. Biochemistry 1987;26:2734.
22. Fruchart JC, Clavey M. Interaction of LpB, LpB:E, LpB:C-III and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of He-La cells. Arterioscler Thromb 1991;11:1021.
23. Alaupovic P, Knight-Gibson C, Wang CS, Downs D, Koren E, Brewer HB Jr, Gregg RE. Isolation and characterization of an ApoA-II-containing lipoprotein (Lp-A-II:B-complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res 1991;32:9.
24. Alaupovic P, Tavella M, Bard JM, Wang CS, Altman PO, Koren E, Corder C, Knight-Gibson C, Downs D. Lipoprotein particles in hypertriglyceridemic states. Adv Exp Med Biol 1988;243:289.
25. Fielding PE, Fielding CJ. An ApoE free very low density lipoprotein enriched in phosphatidylethanolamine in human plasma. J Biol Chem 1986;261:5233.
26. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990;81:470.
27. Alaupovic P, Blankenhorn DH. Characterization of potentially atherogenic triglyceride-rich lipoprotein particles. Klin Wochenschr 1990;60:38.
28. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild to moderate/severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994:90:42.
29. Rafflenbeul W, Heim R, Dzuiba M, Henkel B, Lichtlen PR. Morphometric analysis of coronary arteries. In: Lichtlen PR, ed. Coronary angiography and angina pectoris, Stuttgart: Georg Thieme Verlag, 255-265 (1976).
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499.
31. Curry MD, Alaupovic P, Suenram CA. Determination of apolipoprotein A and its constitutive AI and AII polypeptides by separate electroimmunoassays. Clin Chem 1976;22:315.
32. Curry MD, Gustafson A, Alaupovic P, McConathy WJ. Electroimmunoassay, radioimmunoassay, and radial immunofusion assay evaluated for quantification of human apolipoprotein B. Clin Chem 1978;24:280.
33. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta 1980;617:505.
34. Curry MD, Mcconathy WJ, Alaupovic P, Ledford JD, Popovic M. Determination of human apolipoprotein E by electroimmunoassay. Biochim Biophys Acta 1976; 439:413.
35. Alaupovic P. The biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem 1981;59:565.
36. Koren E, Armstrong VW, Mueller G, Wilson PR, Schuff-Werner P, Thiery J, Eisenhauer T, Alaupovic P, Seidel D. Apolipoprotein A-I and apolipoprotein B-containing lipoprotein particles in coronary patients treated with extracorporal low density lipoprotein precipitation (HELP). Atherosclerosis 1992;95:157.
37. Armstrong VW, Schleef J, Thiery J, Muche R, SchuffWerner P, Eisenhauer T, Seidel D. Effect of Help-LDL-apheresis on serum concentrations of human lipoprotein (a)-kinetic analysis of the post treatment return to baseline levels. Eur J Clin Invest 1989;19:235.
38. Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G, Jacobs D, Frantz ID Jr. Lipoprotein-cholesterol distribution in selected North American populations. The Lipid Research Clinics Program Prevalence Study. Circulation 1980;61:302.
39. Koren E, Corder C, Mueller G, Centurion H, Fesmire J, Hunt L, Alaupovic P. Coronary artery disease and triglyceride enriched lipoproteins. FASEB J 2 (1988) A1596.
40. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesterol esters from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA 1989;86:5810.
41. Nordestgaard BG, Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol 1992;8:92.
42. Musliner TA, Krauss RM. Lipoprotein subspecies and risk of coronary disease. Clin Chem 34 (1988) B-78.
43. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 1981;64:1174.
44. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 1985;71:881.
45. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramaniam S, Baron D, Branson J, Morgan J, Roy P. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atheosclerosis 1987;65:181.
46. Breier CH, Patsch JR, Muhlberger V, Drexel H, Knapp E, Braunsteiner H. Risk factors for coronary artery disease: a study comparing hypercholesterolaemia and hypertriglyceridaemia in angiographically characterized patients. Eur J Clin Invest 1989;19:419.
47. Tornvall P, BÅvenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction, Circulation 1993;88:2180.
48. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762.
49. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473.
50. Gianturco SH, Bradley WA. Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia. Semin Thromb Hemost 1988;14:165.
51. Alaupovic P, Knight-Gibson C, Hodis HN, Mack WJ, Cashin-Hemphill L, Blankenhorn DH. Effect of apoB-containing lipoprotein particles on the progression of atherosclerotic lesions in the Monitored Atherosclerosis Regression Study (MARS). Atherosclerosis 1994;109:154 (abstr.).
52. Koren E, Koscec M, Knight-Gibson C, Lee DM, Alaupovic P. Differential atherogenicity of complex apoB containing lipoprotein particles. Atherosclerosis 1994;109:217 (abstr).